Yazar "Cerrahoglu L." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    LIMPRINT study: The Turkish experience
    (Mary Ann Liebert Inc., 2019) Borman P.; Moffatt C.; Murray S.; Yaman A.; Denizli M.; Dalyan M.; Unsal-Delialioglu S.; Eyigör S.; Ayhan F.; Çaklt B.D.; Vural S.; Özdemir O.; Kurt E.; Çelik E.C.; Cerrahoglu L.; Kepekçi M.; Terzioglu F.; Donmez A.A.
    Background: Lymphedema and chronic edema is a major health care problem in both developed and nondeveloped countries The Lymphoedema Impact and Prevelance-International (LIMPRINT) study is an international health service-based study to determine the prevalence and functional impact in adult populations of member countries of the International Lymphoedema Framework (ILF). Methods and Results: A total of 1051 patients from eight centers in Turkey were recruited using the LIMPRINT study protocol. Data were collected using the core and module tools that assess the demographic and clinical properties as well as disability and quality of life (QoL). Most of the Turkish patients were recruited from specialist lymphedema services and were found to be women, housewives, and having secondary lymphedema because of cancer treatment. The duration of lymphedema was commonly <5 years and most of them had International Society of Lymphology (ISL) grade 2 lymphedema. Cellulitis, infection, and wounds were uncommon. The majority of patients did not get any treatment or advice before. Most of the patients had impaired QoL and decreased functionality, but psychological support was neglected. Although most had social health security access to lymphedema centers, nevertheless access seemed difficult because of distance and cost. Conclusion: The study has shown the current status and characteristics of lymphedema patients, treatment conditions, the unmet need for the diagnosis and treatment, as well as burden of the disease in both patients and families in Turkey. National health policies are needed for the prevention, diagnosis, and treatment in Turkey that utilize this informative data. © Pinar Borman et al. 2019; Published by Mary Ann Liebert, Inc. 2019.
  • Küçük Resim Yok
    Öğe
    Open, prospective, multi-center, two-part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study
    (Galenos Yayincilik,, 2012) Eskiyurt N.; Irdesel J.; Sepici V.; Ugurlu H.; Kirazli Y.; Ardiç F.; Bütün B.; Akyüz G.; Cerrahoglu L.; Şendur Ö.F.; Yalçin P.; Öncel S.; Saridogan M.; Sarpel T.; Tosun M.; Kutsal Y.G.; Şenel K.; Gürsoy S.; Cantürk F.; Demir H.; Özdener F.; Öncel H.
    Aim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7±9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered "YES" to at leastone CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3±17.7 points), quality of life (10.4±20.4points), overall satisfaction (11.9±22.7 points), and side effects (3.3±18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing scheduleand 99.0% were compliant (?80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment.